Citations

Clear

1792 citation(s) found for "Stephanie".

Sleep-Disordered Breathing in Newborns After Myelomeningocele Repair
Hassan, Fauziya, Mason, Thornton, Anadkat, Jagruti, Bendel‐Stenzel, Ellen , Eyerly-Webb, Stephanie, Jon, Cindy, Lloyd, Robin M. , Moldenhauer, Julie S. , Papanna, Ramesha, Pascoe, John E, Reynolds, Regina , Rocque, B., Simakajornboon, Narong , Treadwell, Marjorie C. , Troxler, R. Bradley, Youmans, Lydia , McCaffery, Harlan, Parmar, Hemant A., Merley, Lora, Rau, S M, Chervin, Ronald D., Barks, JD, Bendel-Stenzel, Ellen, Shellhaas, Renée A. , Anadkat, Jagruti , Eyerly‐Webb, Stephanie A. , Papanna, Ramesha , Pascoe, John E. , Riddle, Stefanie , Troxler, Robert Bradley, Kaciroti, Niko , Rau, Stephanie M. , Chervin, Ronald D.

Mayo Clinic

Pediatrics | January 23, 2026 | Volume: 157 | Issue: 2 | Pages: No page available

10.1542/peds.2025-073458 | PMID 41570998 Get It

BACKGROUND & OBJECTIVE Sleep-disordered breathing (SDB) may be a remediable contributor to abnormal cognitive outcomes for children with myelomeningocele. We investigated the frequency of SDB among neonates with fetal vs postnatal myelomeningocele repair. METHODS In this nine-center, prospective, observational study, neonates with myelomeningocele born at more than 30 weeks gestational age underwent a 10-hour bedside polysomnogram at at least 35 weeks postmenstrual age, before hospital discharge. The primary outcome was SDB severity, reflected by the apnea-hypopnea index (AHI; number of respiratory events per hour of sleep). Decisions regarding surgical timing (fetal vs postnatal), technique (open fetal vs fetoscopic approach), and SDB treatment were made by the clinical teams. RESULTS Among 173 infants, 92/173 (53%) had SDB (median AHI 22.5, IQR 12.2–44.2). In unadjusted analysis, AHI was higher among the 90 neonates with fetal repair vs 83 with postnatal surgery (median 29, IQR 14–49, vs 19, IQR 10–36, P = .008). In propensity-adjusted multivariable models, prematurity was independently associated with AHI, whereas surgical timing (fetal vs postnatal) was not. Hindbrain herniation, myelomeningocele level, and clinical need for ventriculoperitoneal shunt did not predict AHI in adjusted models. Supplemental oxygen was commonly prescribed, for 44% of fetal vs 39% of postnatal myelomeningocele repair infants (P = .5). CONCLUSIONS SDB affects more than half of neonates with myelomeningocele. The higher AHI after fetal surgery could stem from the elevated incidence of prematurity in this group. As SDB is treatable and has a potential impact on neurodevelopment, routine screening could become an integral part of a strategy to optimize long-term medical and neurodevelopmental outcomes.
Challenges in Structuring SARS-CoV-2 Emergency Use Authorization Diagnostics Data: Leveraging Findable, Accessible, Interoperable, and Reusable Principles for the Next Era of Diagnostic Data Transparency
Phillips, Alexander J., Glieberman, Aaron L, Gallegos, Christina, Morrison, Anthony , Reed, Michael R., Baron, Veronique T, Dinakar, Karthik , Borchers, Anna, Stone, Webb, Ishack, Stephanie , Rajesh, Singh, Weinstock, Samantha Bates, Luu, Hung S. , Lin, Yu , Merrick, Riki, Luu, Hung S , Phillips, Alexander J., Glieberman, Aaron L. , Gallegos, Christina, Reed, Michael R., Baron, Veronique T. , Borchers, Anna , Okda, Faten A. , Stone, Webb, Don, Sujeewa Sampath Lellupitiyage, Creager, Richard S.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 21, 2026 | Volume: 150 | Issue: 5 | Pages: 381-390

10.5858/arpa.2025-0144-oa | PMID 41386638 Get It

Context.— The US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for SARS-CoV-2 assays encompassed both in vitro diagnostic and laboratory-developed tests. Related testing data and documents from EUAs were published on the FDA website as PDF files, constituting a rich data resource. Objective.— To highlight the value of structured descriptive and validation data and provide recommendations on improving the quality, accessibility, and shareability of the FDA’s digital resources. Design.— SARS-CoV-2 diagnostics EUAs and related files were acquired from the FDA, and data were extracted through an iterative manual or automated process with quality assurance in accordance with a set of data entry definitions to generate a data product (ie, data analysis and presentation of data into tables, graphs, and reports, optionally including different data sets) that could be disseminated. Results.— Four challenges limited the usability of FDA EUA data, including (1) distinguishing EUA tests owing to similar names or inconsistent naming conventions; (2) document location and tracking owing to inconsistent EUA document identifiers, resource locators, and versioning; (3) data location and retrieval owing to heterogeneous structure and data formatting within EUA documentation; and (4) maintenance of existing data owing to lack of clear and traceable communication around EUA amendments. Conclusions.— Converging efforts from disparate groups to extract and synthesize FDA test data reveal an unaddressed need for better organization and communication. Existing FDA data reporting systems must be improved and adapted for the demands of the connected data science era.
Western pediatric cervical spine study: an observational prospective Western Pediatric Surgery Research Consortium and Western Trauma Association multicenter study protocol
Kahan, Anastasia Morgan, Padilla, Benjamin E, Patwardhan, Utsav M , Larsen, Kezlyn, Lee, Justin H, Ostlie, Daniel J. , Jensen, Aaron R. , Ignacio, Romeo C. , Chao, Stephanie D. , Ravindra, Vijay M. , Swendiman, Robert A. , Iyer, Rajiv R. , Brockmeyer, Douglas L. , Kelley-Quon, Lorraine I, Yorkgitis, Brian K. , Inaba, Kenji, Kahan, Anastasia M , Kahan, Anastasia Morgan , Chao, Stephanie D , Russell, Katie , Eldredge, R Scott , Padilla, Benjamin E. , Presson, Angela P. , Melhado, Caroline G. , Kelley‐Quon, Lorraine I. , Escobar, Mauricio Antonio , Inaba, Kenji , Russell, Katie W.

Mayo Clinic

Trauma Surgery & Acute Care Open | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: e001728

10.1136/tsaco-2024-001728 | PMID 41573663 Get It

Background In pediatric patients presenting after blunt trauma, the incidence of clinically significant cervical spine injury (CSI) is approximately 1%. Although multidetector CT (MDCT) is widely accepted for cervical spine clearance in adults, its utility in children remains uncertain. The purpose of this study is to evaluate the sensitivity of MDCT in identifying clinically significant CSI in pediatric patients, stratified by age groups: adolescents (12 years to 17 years) and children (0 years to 11 years). Methods We designed a national, multicenter, prospective observational study to assess the diagnostic performance of MDCT in detecting clinically significant CSI in pediatric trauma patients. Data are being collected from participating centers on imaging findings, clinical outcomes, and the presence of confirmed CSIs after blunt trauma. The analysis plan includes stratification by age group and calculation of sensitivity, specificity, and predictive values of MDCT for CSI. Results This abstract outlines the background, methodology, and analytical framework of the study. Data collection and analysis are ongoing. This study represents the largest known cohort of pediatric patients undergoing cervical spine imaging after blunt trauma and is the first prospective study of its kind focused exclusively on this population. Conclusions This study will provide critical data to inform guidelines for pediatric cervical spine clearance after blunt trauma. By evaluating the sensitivity of MDCT in detecting clinically significant CSI, the findings aim to support evidence-based imaging strategies and improve the safety and efficiency of pediatric trauma care.
An externally validated machine learning model to predict cesarean surgical site infections
Lobel, Megan M. , Wagner, Stephen , Rivera‐Chiauzzi, Enid Y., Wyatt, Michelle A. , Pierce, Stephanie , Dyre, Lillian , Hamel, Maureen, Tuuli, Methodius G. , Lobel, Sam R., Smith, Megan , Rivera‐Chiauzzi, Enid Y. , Wagner, Stephen M , Rivera-Chiauzzi, Enid Y , Pierce, Stephanie L , Dyre, Lillian J

Mayo Clinic

Pregnancy | January 20, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1002/pmf2.70231 | PMID 42597018 Get It

Abstract Objective To develop a comprehensive risk stratification model to identify patients at high risk of cesarean surgical site infection (cSSI) based on information available at the time of hospital discharge. Methods This is a retrospective cohort study based on datasets from two independent level IV academic medical centers to improve generalizability. The first study includes 2336 cesarean deliveries for analysis with 109 instances of cSSI (4.7%). The second study includes 2936 cesarean deliveries with 72 instances of cSSI (2.5%). The first study cohort was utilized for both model training and internal validation, using the 15 shared features present in both datasets. Random search with cross‐validation was used to choose the type of machine learning (ML) model and its hyperparameters, with area under the receiver operating characteristic curve (AUC) as the validation metric. The second study cohort was then used to evaluate testing accuracy (external validation) and generalization capability of this model. The predictive importance of each feature was evaluated using permutation importance applied to the second cohort. Risk stratification cutoff scores were defined based on centiles over the first patient cohort and evaluated on the second cohort. Results The ML model with the highest validation AUC was an XGBoost classifier. This trained model achieved an AUC of 0.78 on the training data and a 0.72 cross‐validated AUC. When tested on data from the second study cohort, it achieved an AUC of 0.69. The features showing the strongest predictive generalization, as measured by permutation importance, were length of hospital stay, primary indication for cesarean delivery, and estimated blood loss. Using the second cohort to test our model, the model shows a 22.7% positive predictive value (PPV) of cSSI among women in the highest risk group, and a 0.8% PPV among women in the bottom risk group, compared with 2.5% cSSI incidence for the study population at large. Conclusion We developed and validated a predictive ML model for cSSI with information available to healthcare professionals at the time of hospital discharge. This model suggests that the most predictive risk factors for cSSI include length of hospital stay, primary indication for cesarean delivery, and estimated blood loss. Additionally, the model provides reasonable risk stratifications for individual patients. This tool may be used for identifying subgroups at higher risk of cSSI and identifying those who may require closer surveillance or clinical intervention.
Epilepsy disease classification: a community effort to enhance the Mondo Disease Ontology
Vasilevsky, Nicole, Gehrke, Sarah , Mullen, Kathleen , Barua, Subit , Braun, Ian , Brünger, Tobias , Ivaniuk, Alina, Korn, Daniel, Lal, Dennis , Marsh, Stephanie, O’Loughlin, Elaine, Olson, Daniel, Shwetar, Yousif, Vanessa, Vogel-Farley, Grabenstatter, Heidi L. , Haendel, Melissa, Mungall, Christopher, Toro, Sabrina, Vasilevsky, Nicole A , Korn, Daniel , Lal, Dennis , Haendel, Melissa , Mungall, Christopher J , Coughlin, Curtis R. , Ivaniuk, Alina , O'Loughlin, Elaine K. , Olson, Daniel , Shwetar, Yousif J. , Sofocleous, Christalena , Vogel‐Farley, Vanessa K. , Haendel, Melissa , Toro, Sabrina

Mayo Clinic

Database | January 14, 2026 | Volume: 2026 | Issue: No issue available | Pages: No page available

10.1093/database/baag004 | PMID 41697974 Get It

Abstract Motivation: Epilepsy is a diverse group of neurological disorders affecting over 50 million people worldwide. While common epilepsy types are well studied, rare epilepsies—often severe and genetically complex—pose significant challenges in diagnosis, research, and treatment. Accurate and interoperable etiology and disease classifications are critical for improving data sharing, supporting clinical decision-making, and advancing rare disease research. Results: To enhance the accuracy of epilepsy-related disease concept representation within the Mondo Disease Ontology (Mondo), we conducted a series of expert-driven workshops in collaboration with the team from the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). Specialists in epileptology, genetics, neurodevelopment, biomedical ontology, and patient community advocates systematically reviewed and revised the epilepsy hierarchy in Mondo, aligning it with the International League Against Epilepsy (ILAE) classification system. These updates include reclassification of epilepsy subtypes, including syndromes, age-related epilepsies, and developmental epileptic encephalopathies, resulting in a more granular, standardized, and clinically relevant structure. Mondo now offers an enhanced framework for integrating epilepsy data across resources, enabling improved interoperability and facilitating rare disease research and data curation, with continued efforts underway to further refine and expand this integration.
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Asken, Breton M., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N., Carrillo, Maria C., Casaletto, Kaitlin B, Cash, David M, Chang, Hsin‐I., Chao, Yishu , Chételat, Gael, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hanseeuw, Bernard J, Hansson, Oskar H., Harrison, Theresa, Huang, Qi, Huang, Shu‐Hua , Ishii, K, Ishii, Kenji, Jagust, William J., Katou, Rikio, Koeppe, Robert A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J, Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis, Rowe, Christopher C., Salvadó, Gemma, Schott, Jonathan M, Schwartz, Daniel, Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz , Silbert, Lisa C, Smith, Ruben, Sokolowski, Andrzej, Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, D., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Vemuri, Prashanthi, Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Joie, Renaud La, Consortia, AMYPAD and LEADS, Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chia‐Hsuin , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kenji, Jagust, William J. , Koeppe, Robert A. , Kramer, Joel H. , Landau, Susan , Landeau, Brigitte , Lee, Sangwon, Lopresti, Brian J. , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , O’Bryant, Sid E. , Pappas, Ioannis , Peretti, Débora Elisa , Quenon, Lisa , Rowe, Christopher C., Salvadó, Gemma , Schott, Jonathan M. , Schwartz, Daniel L., Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villain, Nicolas , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | January 9, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107124 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen's kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure 1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure 1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure 2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure 2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
Reference Handbook of Gynecologic Pelvic MRI
Alexander, Lauren F. , Patel-Lippmann, Krupa , Venkatesan, Aradhana M. , Causa-Andrieu, Pamela, Feldman, Myra K., Desai, Madhura , Law, Wyanne , Mansoori, Bahar , Nicola, Refky, Andrieu, Pamela Causa , Nougaret, Stephanie , Patel-Lippmann, Krupa , Venkatesan, Aradhana M , Causa Andrieu, Pamela , Feldman, Myra , Desai, Madhura A , Mansoori, Bahar , Nicola, Refky , Sadowski, Elizabeth A , Lakhman, Yulia , Alexander, Lauren F , Nougaret, Stéphanie , Feldman, Myra , Sadowski, Elizabeth A. , Lakhman, Yulia

Mayo Clinic

RadioGraphics | January 8, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250029 | PMID 41505283 Get It

The interpretation of gynecologic pelvic MRI benefits from tailored MRI protocols, radiologists' knowledge of normal female pelvic anatomy, and a step-by-step approach focusing on lesion origin, lesion tissue composition, and solid tissue morphology, with findings presented in a structured report.
Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease
Liu, L, Ostaszewski, Beth L., Anderson, Amirah K. , Yau, Wai‐Ying Wendy , Shirzadi, Zahra , Gordon, Brian A., Hassenstab, Jason, Morris, J. Newman, Perrin, Richard J., Allegri, Ricardo F., Barthélemy, Nicolas R., Fox, Nick, Day, Gregory S., Jucker, Mathias, Levey, Allan I., Levin, Johannes, Mori, Hiroshi, Salloway, Stephen, Schofield, Peter, McDade, DO Eric, Sperling, Reisa A., Bateman, Randall J., Selkoe, Dennis J., Chhatwal, Jasmeer P., Network, and the Dominantly Inherited Alzheimer's, Xiong, Chengjie , Hassenstab, Jason , Xiong, Chengjie , Hassenstab, Jason , Schultz, Stephanie A. , Rao, Yiwen, Liu, Lei, Gordon, Brian A. , Perrin, Richard J. , Allegri, Ricardo , Barthélemy, Nicolas R. , Day, Gregory S. , Jucker, Mathias , Levey, Allan I. , Salloway, Stephen , Schofield, PR, McDade, Eric , Sperling, Reisa Anne , Bateman, Randall J. , Selkoe, Dennis J. , Chhatwal, Jasmeer P.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71049 | PMID 41505233 Get It

Abstract INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.
Exploring Prevalence and Drivers of Perimenopause Uncertainty Among U.S. Women: A Mixed-Methods Study
Xu, Yihan, Fergus, Deirbhle, Martin, Yella , Cunningham, Adam , Xu, Yihan , Cunningham, Adam C , Hewings-Martin, Yella , Xu, Yihan , Hedges, Mary S. , Prentice, Carley , Zhaunova, Liudmila , Shufelt, Chrisandra , Faubion, Stephanie S.

Mayo Clinic

No container title available | December 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.24.25342960 Get It

Abstract Objective Perimenopause is an under-recognized life stage that may be accompanied by complex and fluctuating symptoms. We aimed to quantify the prevalence of perimenopause uncertainty and explore the underlying drivers. Methods We conducted a mixed-methods study based on a cross-sectional survey of U.S. women aged 35 years and above (N=7,640). Closed-ended responses were analyzed to estimate the prevalence of perimenopause uncertainty with subgroup differences investigated by age and symptom severity. Content analysis of free-text responses (n=409) was conducted to identify the main uncertainty drivers. Results Overall, 34% of participants reported being unsure of their reproductive stage. Uncertainty peaked among those aged 40-44 (42%) and was highest among those with severe symptom burden (37%). The content analysis revealed three main uncertainty drivers. Symptom confusion and attribution was the most common (56%), reflecting difficulties interpreting bodily changes and distinguishing perimenopause from other causes. Knowledge gaps and information seeking accounted for 28% of responses, highlighting limited health literacy, assumptions about age, and active searches for evidence. Barriers to confirmation and care (16%) described dismissive healthcare encounters and reluctance to acknowledge perimenopause. Younger women (35-39 years) were more likely to cite knowledge gaps, while healthcare barriers peaked in the 40-44 age group. Conclusion Perimenopause uncertainty is a prevalent and clinically meaningful challenge. This uncertainty is conceptually distinct from illness-focused models: it is a universal transition with ambiguity and often lack of validation. Better symptom recognition and targeted communication is a crucial first step toward improving women’s awareness and support during perimenopause.